ciclopirox topical / Generic mfg. - LARVOL DELTA

Lipid nanoparticle co-delivery of mRNA and a small molecule drug for oral cancer chemoimmunotherapy. (PubMed, bioRxiv) - "To overcome these obstacles, we employed a lipid nanoparticle (LNP) that co-encapsulates p53 mRNA and the small molecule ciclopirox (CPX)...When formulated together, our platform provides an all-in-one approach for OSCC, effective in both p53-therapy-susceptible and p53-therapy-resistant models. Additionally, this work provides a template for a delivery platform capable of tackling multiple mechanisms of OSCC progression and survival."

IO biomarker • Journal • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma

Ciclopirox, a broad-spectrum antifungal drug, moonlights as a pyroptosis agonist to drive hepatocellular carcinoma cell death. (PubMed, Eur J Pharmacol) - "In conclusion, CPX exerts its antitumour effects on HCC through ROS-dependent NLRP3-mediated pyroptosis. This study provides a strong rationale for further clinical exploration and development of CPX-based therapies, offering a promising avenue for improving outcomes in patients with HCC."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • NLRP3

Genomic insights into ST85 and ST158 belonging to recently emerged global clones of multidrug-resistant Acinetobacter baumannii isolates from Egypt: in vitro assessment of repurposed drug-antibiotic combinations. (PubMed, Ann Clin Microbiol Antimicrob) - "The current study provides an in-depth characterization of the collected MDRAB isolates from the global clones GC9 and GC10. The endemicity of these clones necessitates strategies to mitigate ongoing MDRAB outbreaks in countries like Egypt. Combination of NAC with meropenem or levofloxacin represents a promising treatment option against the newly emerged global clones that needs further in vivo testing."

Journal • Preclinical • Infectious Disease

Construction and accuracy assessment of an efferocytosis-related prognostic model for ovarian cancer: A diagnostic accuracy study. (PubMed, Medicine (Baltimore)) - "Notably, AFLATOXIN B1 exhibited strong binding affinity to SLC25A45, ciclopirox to BTN3A3, and irinotecan to WDR91. Additionally, significant differences in the IC50 values of 123 anticancer drugs were observed between the 2 risk groups. This findings of this study highlight the efficacy of the efferocytosis-associated risk model in predicting the survival outcomes of OC patients, thus providing a novel reference for prognostic prediction in OC patients."

Biomarker • IO biomarker • Journal • Tumor mutational burden • Oncology • Ovarian Cancer • Solid Tumor • BTNL3 • FCGBP • TMB

STK31-MEDIATED MTOR PHOSPHORYLATION PROMOTES PANCREATIC DUCTAL ADENOCARCINOMA PROGRESSION: MECHANISTIC RESEARCH AND SMALL-MOLECULE INHIBITOR DEVELOPMENT (UEGW 2025) - "AI-driven molecular docking identified ciclopirox as a putative STK31 inhibitor, which was subsequently validated in functional assays... Based on these findings, we propose that STK31 drives PDAC progression via the mTORC2-STAT1-CCNB1/CDC25C axis and that pharmacological inhibition of STK31 represents a viable therapeutic strategy."

Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • AURKB • CCNB1 • CDC25C • GNRP • KRAS

THERAPEUTIC TARGETING OF STK31-MEDIATED ONCOGENIC SIGNALING IN PANCREATIC CANCER (UEGW 2025) - "Based on these findings, we propose that STK31 drives PDAC progression via the mTORC2-STAT1-CCNB1/CDC25C axis and that pharmacological inhibition of STK31 represents a viable therapeutic strategy."

Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • AURKB • CCNB1 • CDC25C • GNRP • KRAS

Ciclopirox suppresses poxvirus replication by targeting iron metabolism. (PubMed, Antiviral Res) - "It also reduced VACV titers in ex vivo mouse lung tissue. These findings highlight host iron metabolism as a critical determinant of poxvirus replication and identify CPX as a promising antiviral candidate against multiple orthopoxviruses."

Journal • Infectious Disease • RRM2

Diode Laser and Red-Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial. (PubMed, Mycoses) - P4 | "Treatment of onychomycosis using diode laser and photodynamic therapy results in higher clinical cure rates and shorter healing times compared to the reference treatment with 8% ciclopirox HPCH."

Clinical • Journal • Infectious Disease

The dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators. (PubMed, Sci Rep) - "While HAP stabilizes the core protein, SBA and Ciclopirox increase flexibility, potentially leading to misassembled or destabilized capsids. These findings contribute to the rational design of CAM-based antiviral therapies and highlight key structural determinants for future drug optimization."

Journal • Hepatitis B • Infectious Disease • Inflammation

Candidal Sycosis: A Case Report (EADV 2025) - "Given the patient's comorbidities and multiple medications, we opted for topical ciclopirox combined with strict hygiene measures... Candidal sycosis is an uncommon fungal infection of the beard area that poses diagnostic and therapeutic challenges. It is often initially mistaken for bacterial or dermatophytic folliculitis, potentially delaying appropriate treatment. Unlike staphylococcal sycosis, which begins with superficial folliculitis and progresses into pustular plaques on a raised erythematous base, Candida sycosis typically presents as painful, inflammatory, multinodular plaques in the beard region, often with pustules and patchy hair loss."

Case report • Clinical • Alopecia • Cardiovascular • Congestive Heart Failure • Cutaneous T-cell Lymphoma • Dermatology • Heart Failure • Hypertension • Infectious Disease • Inflammation • Mycosis Fungoides • Nephrology • Renal Calculi • Renal Disease • Respiratory Diseases • Tuberculosis

Unusual Mycosis in a Metabolic Disorder: Aureobasidium pullulans and Tinea Unguium in a Hypothyroid Patient (EADV 2025) - "The patient was currently taking levothyroxine sodium (100 mcg/day), acetylsalicylic acid (150 mg/day), and sodium alginate + sodium bicarbonate for GERD treatment. Treatment of A. pullulans-associated tinea unguium is challenging due to limited data on antifungal susceptibility. Itraconazole and ciclopirox have been used with varying success. In this case, a combination of oral itraconazole and topical ciclopirox, along with urea-containing emollients, resulted in clinical improvement."

Clinical • CNS Disorders • Dermatology • Endocrine Disorders • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease • Lung Cancer • Metabolic Disorders • Respiratory Diseases • Solid Tumor • Tuberculosis

Hydroxypropyl-Chitosan vs. Poly(pseudo)rotaxane Ciclopirox Nail Lacquers: A Comparative Study (EADV 2025) - "The PRCL ciclopirox lacquer with patented technology has shown improved nail penetration, hydration, and susceptibility to clinical isolates, suggesting an enhanced treatment for nail disorders compared to HPChit. Its higher ciclopirox concentration and increased antifungal activity could potentially contribute to clinical efficacy and address the challenges of this route."

Infectious Disease

Permeation of Ciclopirox from Topical Ciclodextrin-based Medicated Lacquers trough cosmetic Nail polishes (EADV 2025) - "The patented PRCL system has demonstrated enhanced CPX permeation compared to HPChit. Even when cosmetic nail polish is applied, CPX delivered through PRCL exhibits equal or superior effectiveness to HPChit without nail polish."

Infectious Disease

Methylation Enables Sensitive LC-MS/MS Quantification of Ciclopirox in a Mouse Pharmacokinetics Study. (PubMed, Molecules) - "Preliminary PK analysis following intravenous and oral administration in CD-1 mice demonstrated moderate systemic exposure after oral dosing, with an estimated absolute bioavailability of 52.5%. These findings establish the method's suitability and robustness for preclinical and future clinical development of CPX as a repurposed therapeutic agent."

Journal • PK/PD data • Preclinical • Oncology

Trichophyton mentagrophytes ITS genotype VIII/Trichophyton indotineae in Germany-revisit after 5 years (PubMed, Dermatologie (Heidelb)) - "Concurrent topical treatment with azoles, amorolfine, or ciclopirox is always recommended. The off-label use of voriconazole has been reported in isolated cases, and there is also experimental experience with other active ingredients. The spread of TMVIII/TINDO in Germany and worldwide is particularly worrying in view of the dermatophyte's resistance to terbinafine and itraconazole."

Journal • Dermatology • Infectious Disease • SQLE

Onychomycosis in special populations. (PubMed, Future Microbiol) - "Topical antifungals such as efinaconazole, tavaborole, and ciclopirox can be considered for mild to moderate onychomycosis. This review provides an in-depth overview of the epidemiology, diagnosis, and management of onychomycosis in special populations, underscoring the importance of individualized care to improve outcomes and reduce recurrence."

Journal • Review • Dermatology • Diabetes • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Psoriasis • Transplantation

Ciclopirox suppresses poxvirus replication by targeting iron metabolism. (PubMed, bioRxiv) - "It also reduced VACV titers in ex vivo mouse lung tissue. These findings highlight host iron metabolism as a critical determinant of poxvirus replication and support repurposing CPX as a broad-spectrum orthopoxvirus antiviral candidate."

Journal • Infectious Disease • RRM2

Retrospective study of onychomycosis patients treated with ciclopirox 8% HPCH and oral antifungals applying artificial intelligence to electronic health records. (PubMed, Sci Rep) - "The study was conducted to assess the clinical characteristics and outcomes of onychomycosis patients undertaken combined treatment with ciclopirox 8% hydroxypropyl chitosan (CPX 8% HPCH) nail lacquer and oral antifungal agents (terbinafine, itraconazole, and fluconazole). Erythema (5.6%), diarrhea (4.9%), and fever (4.2%) were the most frequently registered potential adverse events. These findings provide valuable insights for physicians regarding the management of patients with onychomycosis in daily practice."

Journal • Retrospective data • Dermatology • Infectious Disease • Mood Disorders

Comprehending the Potential of Topical Therapies for the Treatment of Onychomycosis. (PubMed, Recent Adv Drug Deliv Formul) - "The main challenge associated with topical therapy was found to be the unique structure of the nails, hampering drug penetration to the infection site and inducing fungal drug resistance. Conventional treatment methods, as well as novel techniques developed for topical therapy, like microporation, ionotophoresis, laser, and photodynamic therapy, have also been explored. Oral antifungals are most commonly used for moderate to severe onychomycosis as they provide greater cure rates, whereas topical application of antifungals is advocated for mild to moderate infections as it possesses a better safety profile. Efinaconazole solution (10%), tavaborole solution (5%), and ciclopirox nail lacquer (8%) for topical use are accepted by the Food and Drug Administration (FDA) for the management of onychomycosis. Laser treatment is approved in the United States for the short-term improvement of clear nails in fungal infections, but the clinical outcomes have not yet reached optimal..."

Journal • Infectious Disease

PCNA in Pan-Cancer: A Prognostic Biomarker Unveiled Through a Data-Driven, Multidimensional Analysis of Transcriptomics, Immunity, and Functional Profiling. (PubMed, ACS Omega) - "Unlike previous studies, tumor-specific genetic alterations, such as amplification and hypomethylation, and the paradoxical immune microenvironment linked to PCNA were explored, suggesting potential immune evasion mechanisms. Additionally, new therapeutic avenues reveal PCNA's relationship with drug sensitivity to agents like Navitoclax and Ciclopirox, providing invaluable insights for pharmacological interventions."

Biomarker • Journal • Pan tumor • Oncology • PCNA

Tinea Capitis caused by Trichophyton Benhamiae in two Children: An Emerging Zoophilic Dermatophytic Infection (CDA 2025) - "Both patients were treated with topical ciclopirox and systemic terbinafine for 6 to 8 weeks, resulting in complete resolution of body and scalp lesions, with hair regrowth...Systemic treatment with terbinafine has demonstrated in vitro superiority compared to other antifungals, and no cases of in vitro resistance have been reported. Veterinary treatment of both asymptomatic and symptomatic animals is essential to prevent reinfection."

Clinical • Dermatology • Infectious Disease

ATL001-PII-CEP: A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP (clinicaltrials.gov) - P1/2 | N=6 | Not yet recruiting | Sponsor: Atlas Molecular Pharma

New P1/2 trial • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Rare Diseases

An Assessment of the Antifungal Efficacy of a Novel Topical Onychomycosis Treatment Using Human Nail and Skin Infection Models. (PubMed, J Fungi (Basel)) - "Current topical antifungals like ciclopirox and amorolfine have limited effectiveness, highlighting the need for better treatments...WSNS-PO also prevented the transfer of T. rubrum infection between nails and inhibited the fungal colonization of human skin by dermatophyte and non-dermatophyte fungi and yeast. Together, these results indicate that WSNS-PO possesses fungistatic, barrier-forming, and anti-adhesive properties, suggesting that it holds promise as an onychomycosis treatment against dermatophytes, yeast, and molds."

Journal • Dermatology • Infectious Disease

Antifungal resistance of the Trichophyton mentagrophytes/Trichophyton interdigitale species complex: Insights from the China Antifungal Resistance Dermatophytes Surveillance network Study (CARDS). (PubMed, J Eur Acad Dermatol Venereol) - "The TMTISC was predominantly composed of T. mentagrophytes, followed by T. interdigitale and T. indotineae. A rising trend of reduced azoles susceptibility in TMTISC and multi-drug resistance among T. indotineae isolates has been observed in China."

Journal • Dermatology • Infectious Disease • SQLE

Retrospective Observational Study in Patients With Onychomycosis Treated With Mycoclear® and Ciclopirox (clinicaltrials.gov) - P=N/A | N=80 | Not yet recruiting | Sponsor: University of Bologna

New trial • Infectious Disease